Funding for this research was provided by:
Received: 17 August 2018
Accepted: 17 December 2018
First Online: 22 January 2019
Ethics approval and consent to participate
: All participants provided written informed consent before taking part in the study. The study was approved by the local ethics committee (KA 98155), by the Danish Data Protection Agency, and it was conducted in accordance with the Declaration of Helsinki. The study is registered with ExternalRef removed (NCT00289237).
: Not applicable.
: LJHR has received funding for travel from ViroGates A/S, Denmark. OA and JEO is named inventors on patents on suPAR as a prognostic biomarker. The patents are owned by Copenhagen University Hospital Hvidovre, Denmark. JEO is a shareholder, CSO, and co-founder of ViroGates A/S, Denmark. THH, TK, SL, and CP declare the have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.